Palassini, E. http://orcid.org/0000-0003-2257-4681
Mir, O.
Grignani, G.
Vincenzi, B.
Gelderblom, H.
Sebio, A.
Valverde, C.
Baldi, G. G.
Brunello, A.
Cardellino, G. G.
Marrari, A.
Badalamenti, G.
Martin-Broto, J.
Ferraresi, V.
Libertini, M.
Turano, S.
Gataa, I.
Collini, P.
Tos, A. P. Dei
Gennaro, M.
Bini, F.
Provenzano, S.
Vullo, S. Lo
Mariani, L.
Le Cesne, A.
Casali, P. G.
Article History
Received: 2 October 2021
Accepted: 16 January 2022
First Online: 12 February 2022
Declarations
:
: The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. EP and SP reports institutional financial interest in Advenchen, Amgen-Dompe, Bayer, Epizyme, Eli Lilly, Daiichi-Sankyo, GlaxoSmithKline, Karyopharm, Novartis, Pfizer, PharmaMar, and SpringWorks Therapeutics. OM reports Advisory Board for Bayer, Blueprint Medicines, MSD, Pfizer, Invited Speaker for BMS, Eli-Lilly, Roche, Servier and Institutional, Financial interest as Local PI for Bayer, Blueprint Medicines, Eli-Lilly, Epizyme. AS reports advisory role for Pharmamar and also travel and congress assistance, research, teaching from Pharmamar, teaching, travel and congress assistance from Lilly, Eisai and travel and congress assistance from Merc, Amgen, Sanofi. CV reports Advisory Board for Bayer, Boehringer Ingelheim, GSK, Lilly, Mundipharma, Phar-maMar; Invited Speaker from Roche; Institutional, Financial interest as Local PI from Adap-timmune, Karyopharm, Lilly. GGB reports Honoraria from Eli Lilly, Eisai, PharmaMar and MSD; travel grants from PharmaMar, Pfizer and Eli Lilly; advisory board from Eli Lilly and Glaxo Smith Kline. AB reports Consultancy/Advisory board for Eli Lilly, Eisai, Glaxo Smith Kline; Speakers' fees from PharmaMar; Travel grants from PharmaMar. JMB reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from PharmaMar, Lilly, Bayer, Eisai, Daichii; grants or contracts from Pharmamar, Novartis, Eisai, IMMIX Biopharma; payment for expert testimony from Phar-maMar, Lilly, Bayer, Eisai, Daichii; participation on a Data Safety Monitoring Board or Advisory Board for Roche, Lilly, PharmaMar; Leadership or fiduciary role in board, society, committee or advocacy group for Daiichi Sankyo, Karyopharm, Celgene, Pfizer, BMS, Blueprint, Deciphera, Nektar, Forma, Amgen, Lixte, GEIS, CTOS, ESMO, SELNET. PGC reports honoraria and consultancy or advisory fees from Bayer, Deciphera, Eisai, Eli Lilly, and Pfizer outside the submitted work and institutional financial interest in Advenchen Labora-tories, Amgen Dompe, AROG Pharmaceuticals, Bayer, Blueprint Medicines, Daiichi-Sankyo, De-ciphera, Eisai, Eli Lilly, Epizyme, GlaxoSmithKline, Karyopharm, Novartis, Pfizer, and Pharma-Mar. Other authors: no competing interests to declare.
: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Fondazione IRCCS Istituto Nazionale Tumori di Milano (protocol code 255/20, date 05/11/2020).
: Informed consent was obtained from all subjects involved in the study.